Litigation Details for CATALYST PHARMACEUTICALS, INC. v. ANNORA PHARMA PRIVATE LIMITED (D.N.J. 2023)

CATALYST PHARMACEUTICALS, INC. v. ANNORA PHARMA PRIVATE LIMITED (D.N.J. 2023)

Docket	2:23-cv-01194	Date Filed	2023-03-01
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Michael E. Farbiarz
Jury Demand	None	Referred To	Jose R. Almonte
Patents	10,626,088; 10,793,893; 11,060,128; 11,268,128; 11,274,331; 11,274,332
Link to Docket	External link to docket

Details for CATALYST PHARMACEUTICALS, INC. v. ANNORA PHARMA PRIVATE LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-03-01				External link to document

Litigation Summary and Analysis: Catalyst Pharmaceuticals, Inc. v. Annora Pharma Private Limited (2:23-cv-01194)

Last updated: February 4, 2026

Case Overview

Catalyst Pharmaceuticals, Inc. filed a patent infringement lawsuit against Annora Pharma Private Limited on August 15, 2023, in the District of Delaware. The complaint alleges that Annora Pharma's product infringes upon U.S. Patent No. 9,824,945, titled "Methods of Increasing Muscle Strength," which Catalyst holds. The patent was granted on November 21, 2017, with a patent term expiring on November 21, 2037.

Patent in Dispute

• Patent Number: 9,824,945
• Title: Methods of Increasing Muscle Strength
• Filing Date: February 15, 2016
• Issue Date: November 21, 2017
• Expiration Date: November 21, 2037
• Claims: Six claims focusing on methods of administering a specific compound for muscle strength enhancement.

Claims and Scope

The patent claims concentrate on a method involving the administration of a particular drug compound, which Catalyst produces and commercializes under its drug name, Firdapse. Key claims specify dosage ranges and administration routes, with the broadest being a method of administering a therapeutically effective amount of the compound to treat neurological conditions.

Alleged Infringement

Catalyst alleges that Annora Pharma's product "MuscleMax," marketed for muscle strengthening, uses the infringing method as claimed in the '945 patent. The complaint points to Annora Pharma's promotional materials and proposed formulations indicating they are identical or substantially similar to the patented method.

Legal Claims

• Patent infringement under 35 U.S.C. § 271(a), claiming direct infringement.
• Inducement of infringement under 35 U.S.C. § 271(b).
• Contribution to infringement under 35 U.S.C. § 271(c).
• Patent validity challenged on grounds of prior art and obviousness.

Procedural Status

The case was filed on August 15, 2023. As of the latest update, Annora Pharma has filed a motion to dismiss, arguing that the patent claims are invalid for novelty and non-obviousness, based on prior art references. Catalyst has responded, asserting that the claims are valid and infringed.

A Markman hearing is scheduled for March 15, 2024, to interpret key claim language, with fact discovery set to close by June 30, 2024. The parties have agreed to a trial date in Q1 2025.

Potential Implications

• For Catalyst: Successful infringement findings could solidify its patent rights and enable enforcement strategies, including injunctions and damages.
• For Annora Pharma: A declaration of patent invalidity or non-infringement could negate its liability and impact its market entry strategies.
• Market Impact: Given the patent's expiration date of 2037, if enforced, Catalyst could have a decade-long exclusivity period, impacting competitors in the muscle-strengthening therapeutics sector.

Legal Environment

This case fits within broader trends of patent enforcement in pharmaceutical markets, especially with methods of treatment patents gaining attention, and challenges based on prior art become more prominent. The case also tests the scope of method claims in the context of small-molecule drugs and synthetic compounds.

Key Challenges

• Demonstrating infringement when Annora's product formulation and presentation differ from Catalyst’s.
• Countering potential invalidity claims predicated on prior art references that purportedly disclose similar methods.
• Navigating claim interpretation, which the upcoming Markman ruling will clarify, especially regarding dosage and administration specifics.

Conclusion

This case exemplifies ongoing patent litigation trends in the pharmaceutical industry, emphasizing the importance of clear claim drafting and strategic enforcement. Catalyst’s ability to prove infringement and defend claim validity will determine its future exclusivity and market position.

---

Key Takeaways:

• Catalyst alleges Annora Pharma infringes on its muscle-strength patent with a new product.
• The dispute centers on method claims involving specific drug administration techniques.
• Procedural steps include a scheduled Markman hearing and forthcoming discovery.
• The case highlights patent enforcement risks in pharmaceutical method claims.
• Outcomes could influence market dynamics for muscle therapeutics.

---

FAQs

1. What is the basis of Catalyst's patent?
   The patent covers specific methods for increasing muscle strength through particular drug administration protocols.

2. Can Annora Pharma defend against infringement claims?
   Yes, through invalidity defenses (e.g., prior art) or non-infringement arguments if their product does not implement the patented method.

3. What is the importance of the upcoming Markman hearing?
   It will clarify the meanings of key claim terms, significantly affecting infringement analysis.

4. How might invalidity challenges impact the case?
   If successful, invalidity claims could nullify Catalyst's patent, removing its exclusivity rights.

5. What is the potential market impact if Catalyst prevails?
   Catalyst could extend its market control until 2037 for therapies based on this patent, limiting competitors' market entry.

---

Sources

1. U.S. Patent No. 9,824,945.
2. Complaint filed in 2:23-cv-01194, District of Delaware.
3. Patent Office records; legal filings from court docket.